0001104659-21-085700.txt : 20210728 0001104659-21-085700.hdr.sgml : 20210728 20210625160327 ACCESSION NUMBER: 0001104659-21-085700 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 CORRESP 1 filename1.htm

VIA EDGAR

June 25, 2021

Office of Life Sciences
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Attention: Kasey Robinson and Christopher Edwards

Re:

Aerovate Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-1
File No. 333-256949

Ladies and Gentlemen,

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Aerovate Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 29, 2021, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Edwin M. O’Connor at (212) 813-8853. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Edwin M. O’Connor, by facsimile to (212) 937-3476.

If you have any questions regarding this request, please contact Edwin M. O’Connor of Goodwin Procter LLP at (212) 813-8853.

	Sincerely,

	AEROVATE THERAPEUTICS, INC.

	/s/ Timothy P. Noyes
	Timothy P. Noyes
	Chief Executive Officer

cc:

George A. Eldridge, Aerovate Therapeutics, Inc.

Edwin M. O’Connor, Goodwin Procter LLP

Alicia M. Tschirhart, Goodwin Procter LLP